BioMarin Pharmaceutical Inc. (BMRN) PT Cut to $77 at Nomura as Risks Threaten 1/3 of Revenue
October 24, 2019 6:49 AM
Nomura/Instinet analyst Christopher Marai lowered the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $77.00 (from $93.00) while maintaining ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
